Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy
| Autor: | Mohamed A. Abou-Shady, Amr Elmestikawy, Dina H. Ziada, Ahmed Alwassief, Hossam Shahba, Ashraf Elbahrawy, Mohamed Abdelrazik |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Pyrrolidines Sofosbuvir Immunology Gastroenterology Antiviral Agents Polyethylene Glycols chemistry.chemical_compound Chronic hepatitis Pegylated interferon Simeprevir Virology Internal medicine parasitic diseases Ribavirin medicine Humans Prospective Studies Dual therapy business.industry Gender relations Imidazoles virus diseases Interferon-alpha Valine Cell Biology Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease digestive system diseases Recombinant Proteins Treatment Outcome chemistry Egypt Female Carbamates business medicine.drug |
| Zdroj: | Journal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research. 39(9) |
| ISSN: | 1557-7465 |
| Popis: | In the current study, we aimed to assess the efficacy of different Sofosbuvir (SOF)-based antiviral regimens available in Egypt in the treatment of Pegylated interferon/Ribavirin (PEG-INF/RBV)-experienced chronic hepatitis C virus (HCV) patients. Two hundred fifty-eight patients experienced with PEG-INF/RBV, and 1,283 naive patients were included in the study. The patients received one of the following 3 regimens for 12 weeks; PEG-INF/SOF, Simeprevir/SOF (SIM/SOF), and Daclatasvir/SOF (DCV/SOF). The endpoint was a sustained virological response 12 weeks (SVR12) after the end of the treatment. SVR12, treatment failure, and relapse were assessed. Moreover, predictors of SVR12 were analyzed. The mean age of treatment-experienced and treatment-naive patients was 51.11 ± 5.84 years and 50.04 ± 5.97 years, respectively. Treatment-experienced patients included 132 (51.16%) males and 126 (48.83%) females. Treatment-naive patients included 709 (55.26%) males and 574 (44.73%) females. The SVR12, treatment failure and treatment relapse rates in treatment-experienced versus treatment-naive patients were 91.1% versus 96.8%, 0.8% versus 0.9%, and 8.9% versus 2.7%, respectively. The SIM/SOF regimen provoked a ubiquitous high SVR12 in both treatment-experienced and -naive patients. A SIM/SOF regimen provokes the highest SVR12 in PEG-INF/RBV-experienced chronic HCV patients. Retreatment with PEG-INF/SOF in PEG-INF/RBV-experienced chronic HCV patients has a high probability of treatment failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|